CLICK FOR FULL STORYThe Food and Drug Administration (FDA) confirmed it was reviewing a link between Tysabri and a possible case of the rare brain infection PML. "The case is being reviewed," FDA spokeswoman Lenore Gelb said.

The Boston Globe reported earlier that Biogen, with which Elan developed the treatment, had told the FDA a fourth patient may have contracted PML.